Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT04666272
- Locations
- 🇨🇳
Novartis Investigative Site, Wuhan, China
A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
- Conditions
- Relapsing Multiple Sclerosis
- Interventions
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 63
- Registration Number
- NCT04667117
- Locations
- 🇺🇸
The MS Center for Innovation in Care, Saint Louis, Missouri, United States
🇺🇸Hope Research Institute Center Neurology and Spine, Phoenix, Arizona, United States
🇺🇸Infinity Clinical Research LLC, Hollywood, Florida, United States
Study of Efficacy and Safety of Inclisiran in Japanese Participants With High Cardiovascular Risk and Elevated LDL-C
- Conditions
- HypercholesterolemiaHeterozygous Familial Hypercholesterolemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-12-14
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 312
- Registration Number
- NCT04666298
- Locations
- 🇯🇵
Novartis Investigative Site, Saga, Japan
A First-in-human Study to Investigate the Safety, Tolerability and Pharmacokinetics of MAS825 in Healthy Volunteers
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2022-09-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT04665154
- Locations
- 🇬🇧
Novartis Investigative Site, Mere Way, Nottingham, United Kingdom
An Indian Multi-centric Phase IV Study to Assess the Safety of Crizanlizumab in Sickle Cell Disease Patients
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT04662931
- Locations
- 🇮🇳
Novartis Investigative Site, Kolkata, West Bengal, India
A Non-interventional Study to Assess the Influence of Automated Optical Coherence Tomography Image Enrichment With Segmentation Information on Disease Activity Assessment in Patients Treated With Licensed Anti- VEGF Injections
- Conditions
- Neovascular Age-Related Macular Degeneration
- Interventions
- First Posted Date
- 2020-12-10
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 494
- Registration Number
- NCT04662944
- Locations
- 🇪🇸
Novartis Investigative Site, Leon, Spain
Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia
- Conditions
- Familial Hypercholesterolemia - Homozygous
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 13
- Registration Number
- NCT04659863
- Locations
- 🇺🇸
Excel Medical Clinical Trials LLC, Boca Raton, Florida, United States
🇱🇧Hotel Dieu de France Hospital, Ashrafieh, Lebanon
🇹🇷Novartis Investigative Site, Izmir, Turkey
Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study
- First Posted Date
- 2020-12-08
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 130
- Registration Number
- NCT04657822
- Locations
- 🇺🇸
University Of Alabama, Birmingham, Alabama, United States
🇺🇸Childrens National Hospital, Washington, District of Columbia, United States
🇺🇸Augusta University Georgia, Augusta, Georgia, United States
Digital Adherence Monitoring of Inhalative Therapy in Real- Life Conditions
- Conditions
- Asthma
- Interventions
- Combination Product: MF/IND/GLY plus sensor systemDrug: FDC therapy
- First Posted Date
- 2020-12-07
- Last Posted Date
- 2024-03-25
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 434
- Registration Number
- NCT04656223
- Locations
- 🇩🇪
Novartis Investigative Site, Wiesbaden, Germany
Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Heterozygous Familial Hypercholesterolemia
- Conditions
- Familial Hypercholesterolemia - Heterozygous
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-12-03
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 141
- Registration Number
- NCT04652726
- Locations
- 🇺🇸
Tucson Medical Center, Tucson, Arizona, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Wake Forest U of Health Sciences, Winston-Salem, North Carolina, United States